SCHEMBL5016744

SCHEMBL5016744

OC(CC#Cc1cccnc1)CC#Cc1cccnc1

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.61
CYP2C9 P11712 3/20 0.61
CYP2B6 P20813 3/20 0.61
CYP2C19 P33261 3/20 0.61
CYP2D6 P10635 3/20 0.61
CYP2E1 P05181 2/20 0.61
CYP3A4 P08684 2/20 0.61
CYP1A2 P05177 2/20 0.59
CYP2C8 P10632 1/20 0.59
CHRNB2 P17787 5/20 0.57
CHRNA4 P43681 5/20 0.57
FFAR1 O14842 1/20 0.44
GRM5 P41594 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10398984 0.90 CYP2A6 (0.55) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL10398986 0.90 CYP2A6 (0.55) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL10398983 0.90 CYP2A6 (0.55) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL10397678 0.86 CYP2A6 (0.58) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL10397677 0.86 CYP2A6 (0.58) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL10397676 0.86 CYP2A6 (0.58) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL7055410 0.85 CYP2A6 (0.53) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL12197999 0.82 CYP2A6 (0.62) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL30938347 0.79 CYP2A6 (0.67) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6
SCHEMBL2155811 0.79 CYP2A6 (0.67) CYP2A6CYP2C9CYP2B6CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1138673-B1 Novel carbamates and ureas as modifiers of multi-drug resistance VERTEX PHARMA (US) 2008-08-06 EP disclosed
EP-1666053-A1 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors Vertex Pharmceuticals Incorporated (US) 2006-06-07 EP disclosed
EP-0872466-B1 Process for the synthesis of 1,7-diaryl or 1,7-heteroarylheptan-4-ols and synthetic intermediates FABBRICA ITALIANA SINTETICI SPA (IT) 2002-01-30 EP disclosed
EP-0754176-B1 NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE VERTEX PHARMA (US) 2001-12-05 EP disclosed
EP-1138673-A2 Novel carbamates and ureas as modifiers of multi-drug resistance Vertex Pharmaceuticals Incorporated (US) 2001-10-04 EP disclosed
US-5973157-A Process for the synthesis of 1,7-diarly or heteroaryl-heptane-4-ols and new synthetic intermediates F.I.S. FABBRICA ILTALIANA SINTETICI S.P.A. (IT) 1999-10-26 US disclosed
US-5780484-A Methods for stimulating neurite growth with piperidine compounds VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-07-14 US disclosed
US-5744485-A INCREASE SENSITIVITY OF CELLS; CANCER VERTEX PHARMACEUTICALS INCORPORATED (US) 1998-04-28 US disclosed
EP-0754176-A1 NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE Vertex Pharmaceuticals Incorporated (US) 1997-01-22 EP disclosed
WO-1995026337-A1 NOVEL CARBAMATES AND UREAS AS MODIFIERS OF MULTI-DRUG RESISTANCE VERTEX PHARMACEUTICALS INCORPORATED (US) 1995-10-05 WO disclosed